← Journey Medical Corporation (DERM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Journey Medical Corporation (DERM)
Pharmaceutical Preparations · market cap $204M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Journey Medical Corporation (DERM) is a small commercial-stage specialty dermatology company with 41 employees and an $85M market cap, generating roughly $62M in annual revenue from marketed dermatology products. The company carries a pipeline anchored by DFD-29 (a doxycycline formulation) in Phase 3 for papulopustular rosacea and multiple glycopyrrolate/glycopyrronium programs across Phase 2–3 for hyperhidrosis, with the next scheduled disclosure being Q2 2026 earnings on August 11.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dose 1 of glycopyrrolate, 2.0% QD | Phase 2 | Hyperhidrosis |
| glycopyrrolate, 1.0% | Phase 2 | Hyperhidrosis |
| Glycopyrronium Topical Wipes | Phase 3 | Hyperhidrosis |
| Glycopyrronium cloth, 2.4% | Phase 2 | Palmar Hyperhidrosis |
| DFD-29 | Phase 3 | Papulopustular Rosacea |
| Doxycycline | Phase 3 | Papulopustular Rosacea |
Price & technical context
3-month
-5.2%
6-month
+44.8%
12-month
-5.6%
52-wk range
$4.39–$9.26
vs 50-day MA
-3.2%
vs 200-day MA
-2.2%
Realized vol
67.5%
Max drawdown
-52.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DERM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.